Status:
COMPLETED
Cabazitaxel in Asian Patients With Advanced Gastric Cancer Who Failed Prior Chemotherapy
Lead Sponsor:
Sanofi
Conditions:
Gastric Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Primary Objective: \- To evaluate the anti-tumor activity of cabazitaxel by assessing objective tumor response rate (ORR) at the recommended dose (RD) when administered as a single agent every 3 week...
Detailed Description
Patients will be treated until disease progression, unacceptable toxicity, or patient's refusal of further study treatment. All patients will be followed during and after the study treatment until dea...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Histologically or cytologically confirmed unresectable or metastatic gastric adenocarcinoma including adenocarcinoma of gastroesophageal junction, which have failed 2 prior chemotherapy regimens. (For countries where a standard of care has not been established for the 2nd line treatment for advanced gastric cancer, those who failed 1 or 2 prior chemotherapy regimens can be included)
- Signed informed consent
- Exclusion criteria:
- Patients who have received \>2 prior systemic chemotherapy regimens for advanced gastric cancer.
- For patients entering part 2, those without at least one measurable lesion at baseline according to Response Evaluation Criteria in Solid Tumors 1.1 criteria
- Eastern Cooperative Oncology Group performance status \>1
- Age \<18 years
- Inadequate organ and bone marrow function
- Prior surgery, chemotherapy, targeted agents, investigational agents, or other anti-cancer therapy within 4 weeks prior to enrollment in the study
- Prior radiation therapy within 6 weeks prior to enrollment (except palliative radiation for a local pain control)
- Previous treatment with cabazitaxel
- Known brain or leptomeningeal involvement of cancer
- Patients with known acquired immunodeficiency syndrome (AIDS) related illness or known HIV infection requiring antiretroviral treatment.
- Patients with active varicella zoster infection, or known hepatitis B or C infection.
- History of severe hypersensitivity reaction ≥ grade 3 to drugs formulated with polysorbate 80 such as docetaxel
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Exclusion
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01497964
Start Date
December 1 2011
End Date
May 1 2013
Last Update
November 10 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Investigational Site Number 410001
Seoul, South Korea, 138-736